Focus on national stockpiles

The Company’s initial focus is to develop and market biologic drugs for stockpiling by government agencies. This strategy can expand into co-developing innovative drugs with government partners. The company has also successfully implemented a program conducting contract drug development work and manufacturing for other organizations. Clients have included the Government of Canada and an Asian pharmaceutical company.

In order to seize this growing opportunity, AntoXa is seeking a Series A round of $5 million to advance product opportunities and later will offer a Series B round of $15 million to establish a Canadian manufacturing facility.

By using the vivoXPRESS^® system and its own manufacturing facility, AntoXa will be able to produce affordable medical countermeasures at significantly lower costs compared to competitive products made in traditional mammalian cell culture systems.

AntoXa has the solution to a potentially deadly problem that, although impossible to predict, is almost certain to happen.

AntoXa’s growing portfolio of medical countermeasures addresses the need for effective therapeutics to protect against biological and chemical threats and infectious disease.

• The U.S. Strategic National Stockpile has been allocated USD$50 billion since 2001 to create a national repository of life-saving medical supplies including antitoxins.
• AntoXa has to date secured approximately CAD$4 million towards its medical countermeasure programs and is working with the Canadian, American and Australian departments of defence to prepare for a range of chemical and biological threats.
• Regulators give medical countermeasures a fast track to market and AntoXa is well-positioned to commercialize several products now in development.
• AntoXa’s products address key customer concerns regarding safety, cost and shelf-life.

To learn about investment opportunities, contact:

Don Stewart, CEO
[email protected]
416.452.7242
1920 Yonge Street, Suite 200
Toronto, Ontario, Canada,  M4S 3E2